Skip to Content

Fasenra (benralizumab) Disease Interactions

There is 1 disease interaction with Fasenra (benralizumab):

Moderate

Benralizumab (applies to Fasenra) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Anti-benralizumab antibodies were associated with increased clearance of benralizumab and increased blood eosinophil levels in patients with high anti-drug antibody titers compared to antibody negative patients. Eosinophils may be involved in the immunological response to some helminth infections. It is recommended to treat patients with preexisting helminth infections before starting therapy with benralizumab. Treatment should be discontinued if patients become infected while on treatment, and do not respond to helminth treatment. Treatment may be restarted once infection resolves.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.